WHO ICTRP trial
A Phase 2 study to assess the safety, immunogenicity and recommended dose of…
JPRN-jRCT2071210086 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2071210086 |
|---|---|
| Public title | A Phase 2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adults |
| Scientific title | A Phase 2 study to assess the safety, immunogenicity and recommended dose of DS-5670a (COVID-19 vaccine) in Japanese healthy adults |
| Primary sponsor | Inoguchi Akihiro |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | Prevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) |
| Interventions | Part 1 and Part 2: Administer 30 or 60 ug of DS-5670a intramuscularly twice. 3rd administration part: Administer 60 ug of DS-5670a intramuscularly once. |
| Registration date | Oct 29, 2021 |
| Target size | 80 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: